Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Trial details
- Registry ID
- NCT02174419
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as nalbuphine ER
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisNCT02174419 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2016-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |